Literature DB >> 25336712

Overtreatment in couples with unexplained infertility.

F A M Kersten1, R P G M Hermens2, D D M Braat1, A Hoek3, B W J Mol4, M Goddijn5, W L D M Nelen6.   

Abstract

STUDY QUESTION: What is the percentage of overtreatment, i.e. fertility treatment started too early, in couples with unexplained infertility who were eligible for tailored expectant management? SUMMARY ANSWER: Overtreatment occurred in 36% of couples with unexplained infertility who were eligible for an expectant management of at least 6 months. WHAT IS KNOWN ALREADY: Prognostic models in reproductive medicine can help to identify infertile couples that would benefit from fertility treatment. In couples with unexplained infertility with a good chance of natural conception within 1 year, based on the Hunault prediction model, an expectant management of 6-12 months, as recommended in international fertility guidelines, prevents unnecessary treatment. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study in 25 participating clinics, with follow-up of all couples who were seen for infertility in 2011-2012. PARTICIPANTS/MATERIALS, SETTING,
METHODS: In all, 9818 couples were seen for infertility in the participating clinics. Couples were eligible to participate if they were diagnosed with unexplained infertility and had a good prognosis of natural conception (>30%) within 1 year based on the Hunault prediction model. Data to assess overtreatment were collected from medical records. Multilevel regression analyses were performed to investigate associations of overtreatment with patient and clinic characteristics. MAIN RESULTS AND THE ROLE OF CHANCE: Five hundred and forty-four couples eligible for expectant management were included in this study. Among these, overtreatment, i.e. starting medically assisted reproduction within 6 months, occurred in 36%. The underlying quality indicators showed that in 34% no prognosis was calculated and that in 42% expectant management was not recommended. Finally, 16% of the couples for whom a correct recommendation of expectant management for at least 6 months was made, started treatment within 6 months anyway. Overtreatment was associated with childlessness, higher female age and a longer duration of infertility. No associations between overtreatment and clinic characteristics were found. LIMITATIONS, REASONS FOR CAUTION: The response rate was low compared with other fertility studies. Evaluation of possible selection bias showed that responders had a higher socio-economic status than non-responders. WIDER IMPLICATIONS OF THE
FINDINGS: Our findings show that developing and publishing guideline recommendations on tailored expectant management (TEM) is not enough and that overtreatment still occurs frequently. Future research should focus on tailored efforts to implement guideline recommendations on TEM. STUDY FUNDING/COMPETING INTERESTS: Supported by Netherlands Organisation for Health Research and Development (ZonMW). ZonMW had no role in designing the study, data collection, analysis and interpretation of data or writing of the report. Competing interests: none. TRIAL REGISTRATION NUMBER: www.trialregister.nl NTR3405.
© The Author 2014. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  expectant management; guideline adherence; implementation; prognostic models; unexplained infertility

Mesh:

Year:  2014        PMID: 25336712     DOI: 10.1093/humrep/deu262

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  'Genes versus children': if the goal is parenthood, are we using the optimal approach?

Authors:  Jackson C Kirkman-Brown; Mariana V Martins
Journal:  Hum Reprod       Date:  2020-01-01       Impact factor: 6.918

2.  IVF for unexplained subfertility; whom should we treat?

Authors:  R van Eekelen; N van Geloven; M van Wely; S Bhattacharya; F van der Veen; M J Eijkemans; D J McLernon
Journal:  Hum Reprod       Date:  2019-07-08       Impact factor: 6.353

3.  International Natural Procreative Technology Evaluation and Surveillance of Treatment for Subfertility (iNEST): enrollment and methods.

Authors:  Joseph B Stanford; Tracey Parnell; Kristi Kantor; Matthew R Reeder; Shahpar Najmabadi; Karen Johnson; Iris Musso; Hanna Hartman; Elizabeth Tham; Ira Winter; Krzysztof Galczynski; Anne Carus; Amy Sherlock; Jean Golden Tevald; Maciej Barczentewicz; Barbara Meier; Paul Carpentier; Karen Poehailos; Robert Chasuk; Peter Danis; Lewis Lipscomb
Journal:  Hum Reprod Open       Date:  2022-08-09

4.  The needs of subfertile couples continuing to attempt natural conception: in-depth interviews.

Authors:  Felicia Dreischor; Ellen T M Laan; Fleur Peeters; Karen Peeraer; Cornelis B Lambalk; Mariëtte Goddijn; Inge M Custers; Eline A F Dancet
Journal:  Hum Reprod Open       Date:  2022-09-15

5.  Cost-effectiveness of medically assisted reproduction or expectant management for unexplained subfertility: when to start treatment?

Authors:  R van Eekelen; M J Eijkemans; M Mochtar; F Mol; B W Mol; H Groen; M van Wely
Journal:  Hum Reprod       Date:  2020-09-02       Impact factor: 6.918

6.  The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART.

Authors:  Veljko Vlaisavljevic; Susanna Apter; Antonio Capalbo; Arianna D'Angelo; Luca Gianaroli; Georg Griesinger; Efstratios M Kolibianakis; George Lainas; Tonko Mardesic; Tatjana Motrenko; Sari Pelkonen; Daniela Romualdi; Nathalie Vermeulen; Kelly Tilleman
Journal:  Hum Reprod Open       Date:  2021-07-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.